GenX (HFPO Dimer Acid) Toxicology and Liver and Immune Toxicity

RoseyFields evaluates the toxicology of GenX using the following evidence base.

Chemical Identity and Physicochemical Properties Relevant to Toxicity

“GenX chemicals” refers to hexafluoropropylene oxide dimer acid (HFPO-DA; CASRN 13252-13-6) and its ammonium salt (CASRN 62037-80-3), a short-chain perfluoroether carboxylic acid within the broader per- and polyfluoroalkyl substances (PFAS) class, used since 2009 as a processing aid in fluoropolymer manufacture and as a replacement for perfluorooctanoic acid (PFOA).

Several physicochemical properties are directly relevant to interpreting the toxicological evidence base. HFPO-DA and its ammonium salt are highly water soluble and, at the pH levels typically found in biological and environmental systems, exist almost entirely as the dissociated propionate (carboxylate) anion rather than the neutral acid, a property they share with other perfluoroalkyl carboxylic acids and one that governs both their environmental mobility and their handling within the body. They are stable to hydrolysis and direct photolysis, and available biodegradation data indicate they are persistent, with an environmental half-life exceeding six months in air, water, soil, and sediment; they are not expected to be removed by conventional drinking-water or wastewater treatment. Unlike legacy long-chain PFAS such as PFOA and PFOS, GenX chemicals show comparatively low bioaccumulation potential in aquatic organisms — a related short-chain perfluoroether, HFPO-trimer acid, showed a fish bioaccumulation factor below 10 in one study used as a supporting comparator (Pan et al., 2017) — consistent with more rapid renal clearance relative to the long-chain PFAS the GenX technology was designed to replace. This combination of high water solubility, environmental persistence, and comparatively rapid biological clearance (discussed further in Section 3) is the central physicochemical narrative for GenX toxicology: it is persistent enough in the environment to result in sustained exposure at contaminated sites, but eliminated from the body far faster than the legacy PFAS it replaced, which has direct implications for how animal dosing regimens translate to human risk.

Toxicokinetics: Absorption, Distribution, Metabolism, and Excretion

Oral absorption of HFPO-DA and its ammonium salt is rapid and essentially complete in laboratory animals; in single-dose oral gavage studies, urinary and plasma recovery data account for the great majority of the administered dose within days, with no evidence that gastrointestinal absorption is a limiting step.

Metabolism is minimal to absent. In vitro incubations of HFPO-DA ammonium salt with viable rat hepatocytes showed no difference in test-substance concentration compared to heat-inactivated (metabolically inert) hepatocyte controls, and no metabolites were detected, indicating the compound is not appreciably metabolized by rat liver tissue; single-dose oral studies in rats and mice likewise recovered the parent compound essentially unchanged in urine, with no metabolites identified. This lack of metabolism means that, unlike many organic toxicants, HFPO-DA’s toxicokinetics are governed almost entirely by absorption, protein-mediated distribution, and renal excretion of the unchanged parent anion, rather than by the formation of reactive or otherwise toxic metabolites.

Distribution and elimination show pronounced, and toxicologically important, species and sex differences, most comprehensively characterized in a peer-reviewed toxicokinetic analysis pooling data from single-dose oral and intravenous studies in rats, mice, and cynomolgus monkeys (Gannon et al., 2016). Urine is the dominant excretory pathway in all three species; fecal elimination is minor. Within rats, female rats clear HFPO-DA anion substantially faster than male rats — in one cross-species intravenous dosing study, plasma concentrations in male rats were roughly one to two orders of magnitude higher than in females at comparable time points, and the elimination-phase half-life was approximately four times longer in male rats than in female rats. This sex difference is understood to reflect more efficient active renal tubular secretion of the anion in female rats, a phenomenon well documented for other perfluoroalkyl acids and generally attributed to sex-hormone-dependent expression of renal organic anion transporters. The pattern is reversed in mice: female mice clear the compound somewhat faster than male mice, but the magnitude of the mouse sex difference is smaller than in rats, and mice as a species clear HFPO-DA considerably more slowly than rats of either sex — oral-dose elimination half-lives in one analysis were on the order of 25–37 hours in mice versus roughly 67–72 hours (a longer, not shorter, apparent half-life once both distribution and elimination phases are modeled together) in rats, illustrating that simple species comparisons can be counterintuitive depending on which pharmacokinetic parameter and dosing route are compared (Gannon et al., 2016). A parallel single-dose comparison, using a cruder “plasma clearance time” metric rather than formal half-life modeling, similarly found clearance was fastest in female rats, intermediate in male rats, and slowest in mice of both sexes.

Notably, repeated daily dosing does not simply reproduce single-dose kinetics. In a 28-day repeated-dose mouse study, serum HFPO-DA concentrations failed to reach a stable steady state within the time predicted from single-dose half-life estimates and instead continued to change between days 5 and 28 of dosing, with males consistently showing higher serum and urine concentrations than females at each measured time point (Rushing et al., 2017). This finding indicates that HFPO-DA toxicokinetics are more dynamically complex under repeated exposure than standard one- or two-compartment pharmacokinetic models capture, a point of direct relevance to interpreting subchronic and chronic study dose-response data.

The only available human toxicokinetic information comes from an unpublished, non-peer-reviewed industry dataset: paired pre- and post-weekend blood samples from twenty-five Chemours facility workers in the Netherlands yielded an average estimated serum half-life of approximately 81 hours, with a wide range (42–333 hours) across individuals and no stratification by sex. Even taking this estimate at face value, it is far shorter than the multi-year serum half-lives reported for legacy long-chain PFAS such as PFOA and PFOS in humans, reinforcing that GenX’s shorter-chain structure achieves its intended design goal of more rapid elimination relative to the chemicals it replaced, even though the exact human elimination rate — and whether it differs by sex as it does in rats — remains only weakly characterized.

Mechanism and Mode of Action

The most extensively studied and best-supported mechanism for HFPO-DA hepatotoxicity is activation of peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor that regulates hepatic lipid and fatty-acid metabolism genes and is a well-established mediator of hepatocellular hypertrophy, peroxisome proliferation, and, with sufficiently potent and persistent activation, hepatocellular tumor formation in rodents. Hepatic transcriptomic analyses in pregnant and non-pregnant rats and mice exposed to HFPO-DA consistently show upregulation of PPARα target genes involved in peroxisomal and mitochondrial fatty-acid beta-oxidation, alongside broader activation of PPAR-beta/delta and PPAR-gamma target genes (Conley et al., 2019, 2021). In vitro receptor-binding and reporter-gene assays confirm that HFPO-DA can activate PPAR-gamma specifically, with somewhat different binding affinity for the human versus mouse PPAR-gamma ligand-binding domain (Li et al., 2019), indicating that HFPO-DA’s nuclear receptor activity is not confined to PPARα alone.

Two lines of evidence complicate a simple, exclusively PPARα-driven explanation. First, transmission electron microscopy of maternal liver tissue from HFPO-DA-exposed pregnant mice found increased numbers of mitochondria, a finding not typical of PPARα activation alone and one that, together with upregulation of genes specific to mitochondrial beta-oxidation, ketogenesis, and electron transport, suggests an additional, PPARα-independent mitochondrial mechanism may also contribute to the hepatic effects (Blake et al., 2020; Conley et al., 2019). Second, and more generally, transcript-profiling work across multiple perfluoroalkyl acids has found that a meaningful fraction (on the order of 11–24%, depending on the specific compound) of the hepatic transcriptional response to PFAS exposure occurs independently of PPARα, in both wild-type and PPARα-null mice (Rosen et al., 2017), indicating that a purely PPARα-centric mode-of-action model likely does not capture the full biological picture for this chemical class generally, and specifically for the constellation of liver lesions used as the critical noncancer endpoint for HFPO-DA (Rushing et al., 2017; DuPont-18405-1037, 2010).

For the immune effects observed in mice (Section 5), the specific molecular mechanism is not established; suppression of the T-cell-dependent antibody response is a well-recognized immunotoxicological endpoint for several PFAS, but the receptor or signaling pathway responsible for HFPO-DA’s effect on this endpoint specifically has not been characterized to the same degree as the hepatic PPAR pathways.

The distinction between a rodent-specific PPARα-driven mechanism and a broader, potentially more human-relevant set of mechanisms is not a peripheral academic question: it is the central point of scientific and regulatory dispute over how much weight the rodent hepatic tumor and lesion data should carry in human risk assessment, discussed further in Section 7.

Animal Toxicological Evidence by Organ System

Hepatic. The liver is the most consistently affected organ across the entire HFPO-DA database, with effects observed in both sexes, in rats and mice, and across exposure durations from 28 days to two years and doses from approximately 0.1 to 1,000 mg/kg-day. Findings include increased relative liver weight, hepatocellular hypertrophy (cytoplasmic alteration), single-cell and focal necrosis, hepatocellular apoptosis, altered liver enzymes (increased ALT, AST, ALP, and SDH in some studies; a comparatively unusual and consistent decrease in serum bilirubin and cholesterol across multiple studies, discussed further in Section 7), and, at the highest chronic dose, hepatocellular tumors (Section 6). The most sensitive endpoint identified — a “constellation” of related, dose-responsive liver lesions (cytoplasmic alteration, single-cell necrosis, focal necrosis, and apoptosis) in parental female mice in an oral gavage reproduction/developmental toxicity screening study — occurred at a no-observed-adverse-effect level of 0.1 mg/kg-day and a lowest-observed-adverse-effect level of 0.5 mg/kg-day (DuPont-18405-1037, 2010), findings independently confirmed by consensus histopathological re-review (Section 4) and corroborated in a separate 90-day subchronic mouse study (DuPont-18405-1307, 2010) and in RNA-sequencing analyses of hepatotoxic mechanism (Wang et al., 2017).

Immune. In a 28-day repeated-dose gavage study in C57BL/6 mice, HFPO-DA suppressed the T-cell-dependent antibody response, measured as sheep-red-blood-cell-induced immunoglobulin M production, which decreased by approximately 7% in high-dose females relative to controls, alongside other immune parameter changes (Rushing et al., 2017). This remains the only dedicated immunotoxicity study identified for HFPO-DA, a limitation discussed further in Section 8.

Renal. Increased relative kidney weight, generally without accompanying histopathological lesions, is a repeated finding across short-term, subchronic, and reproductive/developmental studies in both rats and mice, observed dose-dependently in several studies (e.g., DuPont-17751-1026, 2009; DuPont-18405-1037, 2010). This pattern — organ-weight change without a corresponding pattern of overt tissue injury — is consistent with an adaptive or compensatory renal response related to increased renal clearance workload (Section 3) rather than a direct nephrotoxic lesion, though the available database does not permit a fully confident distinction between these possibilities.

Cardiovascular/lipid. HFPO-DA exposure consistently decreases serum cholesterol and triglyceride levels across multiple rat and mouse studies, in some cases with reductions exceeding 25% relative to control at higher doses. This finding is notable because, as discussed in Section 7, it is directionally opposite to associations reported in human epidemiological studies of other, structurally related PFAS and serum lipids, and is one of the clearest examples in the HFPO-DA database of an animal finding whose direct translation to expected human effect is genuinely uncertain.

Developmental. Gestational exposure studies in rats are the most extensive component of the HFPO-DA developmental database. Findings include accelerated parturition (earlier delivery), reduced pup birth weight, increased neonatal mortality, maternal and fetal hepatomegaly, and disrupted maternal and fetal glucose and lipid metabolism (Conley et al., 2019, 2021); altered maternal and fetal/placental thyroid hormone concentrations (reduced total T3 and T4) have also been reported (Conley et al., 2019, 2021; Blake et al., 2020), a finding of particular concern given thyroid hormone’s established role in fetal neurodevelopment. A comparative mouse study directly evaluating maternal, embryo, and placental effects of HFPO-DA alongside PFOA found overlapping but not identical effect profiles between the two chemicals, including changes in maternal serum lipid parameters and hepatic ultrastructure (Blake et al., 2020). A prenatal developmental toxicity study in rats (DuPont-18405-841, 2010) similarly reported maternal hepatotoxicity and fetal effects following gestational-window dosing.

Reproductive. In the oral reproduction/developmental toxicity screening study in mice that also produced the critical hepatic endpoint (Section 3), reproductive findings included delays in offspring genital development, measured in part via anogenital distance, a recognized marker of androgen-pathway disruption in rodent developmental toxicology (DuPont-18405-1037, 2010). The chronic 2-year rat bioassay (Section 6) additionally reported non-statistically-significant but dose-related increases in testicular interstitial (Leydig) cell hyperplasia and adenoma at the highest dose tested (Caverly Rae et al., 2015).

Endocrine. Beyond the thyroid hormone changes noted under developmental effects above, dedicated endocrine-specific toxicological investigation of HFPO-DA is limited; most thyroid and reproductive-hormone-relevant data derive from the developmental and reproductive study designs described above rather than from studies purpose-built to evaluate endocrine endpoints.

Neurological. No dedicated neurotoxicity studies of HFPO-DA in animals were identified in the available database; this is a notable data gap discussed further in Section 8, particularly given the reported thyroid hormone perturbations, which are mechanistically linked to neurodevelopmental outcomes for other thyroid-disrupting chemicals.

Animal Carcinogenicity Bioassay Findings

A single chronic bioassay is available: a combined 2-year oral gavage chronic toxicity/oncogenicity study in Sprague-Dawley rats at doses of 0, 1, 50, and 500 mg/kg-day (DuPont-18405-1238, 2013; published in the peer-reviewed literature as Caverly Rae et al., 2015). At the highest dose (500 mg/kg-day), female rats showed statistically significant, dose-related increases in hepatocellular adenoma (11/70, 15.7%, versus 0/70 in control) and hepatocellular carcinoma (4/70, 5.7%, versus 0/70 in control), both exceeding the testing laboratory’s historical control ranges. At 50 mg/kg-day, male rats showed a statistically significant increase in combined pancreatic acinar cell adenoma and carcinoma (5/70, 7.1%, versus 0/70 in control), driven by carcinoma incidence (2/70) that itself modestly exceeded the historical control range, while pancreatic acinar cell hyperplasia showed no consistent dose-response pattern across groups. Also at 50 mg/kg-day, male rats showed a non-statistically-significant increase in testicular interstitial (Leydig) cell adenoma (8/70, 11.4%, versus 4/70 in control) that nonetheless exceeded the historical control range; a substantial number of early, non-tumor-related deaths in this study complicated interpretation of the testicular finding, and a reanalysis excluding early deaths did not change the conclusion that the Leydig cell finding was not statistically significant. The study authors themselves concluded that a treatment relationship for the testicular finding “cannot be ruled out” while separately noting that Leydig cell tumor induction in rodents is a recognized phenomenon with generally low relevance to humans, reflecting a well-characterized rodent-specific hormonal mechanism (Caverly Rae et al., 2015).

Considered together, this single bioassay provides statistically robust evidence of liver and pancreatic tumor induction in rats at high, generally near-maximum-tolerated doses, with the testicular finding considerably more equivocal. No chronic bioassay in mice — the species shown to be more sensitive to HFPO-DA’s noncancer hepatic effects (Section 5) — is available, leaving a notable gap in cross-species carcinogenicity characterization discussed further in Section 8.

Comparison to Human Epidemiological Findings and Sources of Divergence

No epidemiological studies specifically evaluating human health effects of HFPO-DA exposure are available in the published literature, in sharp contrast to the extensive human cohort literature (including the C8 Health Project) that exists for legacy long-chain PFAS such as PFOA and PFOS. This absence of chemical-specific human data means RoseyFields’ assessors cannot directly validate any of the animal findings described in Section 5 against a human epidemiological benchmark for HFPO-DA itself, and must instead reason by analogy to the broader PFAS class while remaining explicit about the limits of that analogy.

The clearest illustration of why animal and human PFAS findings can diverge, and a point directly relevant to interpreting the HFPO-DA hepatic and lipid data, is the well-documented “PFAS lipid paradox”: animal studies of PPARα-activating PFAS, including HFPO-DA specifically (Section 5), consistently show decreased serum cholesterol and triglycerides, whereas human epidemiological studies of structurally related legacy PFAS (principally PFOA and PFOS) have repeatedly found the opposite association — increased, not decreased, serum cholesterol. The leading explanation for this divergence is a genuine species difference in PPARα biology: humans express hepatic PPARα at substantially lower levels than rodents and mount a quantitatively and qualitatively different, more muted transcriptional response to PPARα activation, such that the lipid-lowering, peroxisome-proliferating, and ultimately tumorigenic cascade well documented in rodent liver following sustained PPARα activation does not straightforwardly translate to human hepatocytes (Corton et al., 2014). This species difference is central to the ongoing scientific and regulatory dispute over the human relevance of HFPO-DA’s rodent hepatic tumor findings (Section 6): if human hepatic PPARα activity is genuinely too limited to reproduce the rodent mode of action, the rodent tumor data may substantially overstate human cancer risk; if, as EPA’s final assessment concluded, the available data are insufficient to confirm that human PPARα-related processes are adequately protective at relevant exposure levels, or if PPARα-independent mechanisms (Section 4) contribute meaningfully to the human-relevant hazard, the rodent findings retain their default regulatory weight. RoseyFields’ assessors treat this as a genuinely unresolved scientific question rather than one with a settled answer in either direction, and disclose the manufacturer funding of the principal papers arguing for reduced human relevance (Section 8) whenever that literature is invoked to argue for a higher acceptable human exposure level than the rodent-based values would otherwise support.

A second source of likely divergence is toxicokinetic: the pronounced sex differences in rodent renal clearance of HFPO-DA (Section 3) have no confirmed human counterpart, because the only available human half-life dataset was not stratified by sex; if a similar sex difference exists in humans, dose reconstruction and risk characterization that do not account for it could be systematically biased for one sex or the other, a limitation RoseyFields’ assessors disclose explicitly in any matter where sex-specific exposure or outcome patterns are at issue.

Data Gaps and Areas of Ongoing Research

Several data gaps meaningfully limit confidence in extrapolating the current animal toxicological database to human risk. No chronic-duration study exists in mice, the species and sex combination (female mice) that produced the most sensitive noncancer hepatic point of departure, leaving genuine uncertainty about whether chronic mouse exposure would produce liver tumors at doses comparably low to, or even lower than, those producing tumors in the chronic rat bioassay. Only a single, 28-day immunotoxicity study is available, precluding any assessment of whether immune suppression persists, worsens, or attenuates with longer-duration or lower-dose exposure, or whether it occurs by a mode of action mechanistically linked to the hepatic PPAR pathways or is independent of them. No dedicated neurotoxicity study has been conducted, a gap of particular concern given the documented thyroid hormone perturbations in gestationally exposed animals and thyroid hormone’s well-established role in neurodevelopment. No validated physiologically based toxicokinetic model exists for HFPO-DA, and the only available human toxicokinetic dataset is unpublished, not peer reviewed, limited to eighteen individuals with usable data, and not stratified by sex, despite a documented sex difference in the rodent data. The mode of action underlying the critical hepatic lesions remains only partially resolved, with active, manufacturer-funded research continuing to advance a PPARα-predominant, reduced-human-relevance interpretation (Section 4) that EPA’s own final assessment has, to date, declined to adopt. Finally, no studies to date have evaluated combined or cumulative exposure to HFPO-DA alongside co-occurring PFAS at contaminated sites, even though environmental monitoring at known GenX-impacted locations routinely detects multiple PFAS simultaneously, meaning the existing single-chemical toxicological database may not fully characterize real-world combined exposure risk.

Bibliography